Betadex

Summary

Betadex (CHEMBL415690) is a phase-3 clinical-stage oligosaccharide.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligosaccharide
• Clinical trials: 1
• Chemistry: 1135 Da · C42H70O35

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL415690
Name	Betadex
Type	Oligosaccharide
Max phase	3
FDA approved	no
PubChem CID	444041
ChEBI	CHEBI:495055
Molecular formula	C42H70O35
Molecular weight	1135
InChIKey	WHGYBXFWUBPSRW-FOUAGVGXSA-N

SMILES: C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O

IUPAC name: (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol

ChEBI definition: A cyclodextrin composed of seven α-(1→4) linked D-glucopyranose units.

Also known as: .beta.-cyclodextrin, Beta cyclodextrin, Beta-cyclodextrin, Beta-schardinger dextrin, Betacd, Betadex, Cavamax w7, Cyclodextrin b, Cyclodextrin, beta-, Cycloheptaamylose, Cycloheptaglucan

Patent coverage: 38,934 distinct patent families (83,677 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp, Thyrotropin receptor, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TSHR	7.8	Potency	15.8	nM	CHEMBL_ACT_3915456
TSHR	7.8	Potency	15.8	nM	CHEMBL_ACT_4719129

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01960621	PHASE4	WITHDRAWN	Effect of Cyclodextrin on Sensory Nerve Activity: A Novel Anti-tussive Therapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).